Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia

Folia Histochemica et Cytobiologica

Volumn 49, Issue 1, 2011, Pages 161-167

  Giannopoulos, Krzysztof ^a   Własiuk, Paulina ^a   Dmoszyńska, Anna ^a   Roliński, Jacek ^a   Schmitt, Michael ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

B cell chronic lymphocytic leukemia (CLL); Peptide immunotherapy; Receptor for hyaluronic acid mediated motility (RHAMM)

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; PEPTIDE VACCINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CD8+ CD103+ T LYMPHOCYTE; CD8+ CD137+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; LONGITUDINAL STUDY; MALE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TUMOR IMMUNITY;

EID: 79958130398     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0023     Document Type: Article

References (29)

1. Keating MJ, Chiorazzi N, Messmer B et al. Biology and treatment of chronic lymphocytic leukemia. Hematology ASH Educ Program. 2003;153-175.
2. Hallek M, Cheson BD, Catovsky D et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lym-phocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-5456.
3. Robak T, Dmoszynska A, Solal-Céligny P et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophospha-mide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756-1765
4. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2009:602-609.
5. ten Cate B, de Bruyn M, Wei Y, Bremer E, Helfrich W. Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr Drug Targets. 2010;11:95-110.
6. + regulatory T cells toward an antileuke-mia response. Leukemia. 2008;22:1007-1017.
7. Hus I, Roliński J, Tabarkiewicz J et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immu-notherapy for patients with early-stage B-cell chronic lympho-cytic leukemia. Leukemia. 2005;19:1621-1627.
8. Palma M, Adamson L, Hansson L et al. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. Cancer Immunol Immunother. 2008;57:1705-1710.
9. Giannopoulos K, Schmitt M. Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47:2028-2036.
10. Giannopoulos K, Li L, Bojarska-Junak A et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol. 2006;29:95-103.
11. Giannopoulos K, Mertens D, Bühler A et al.The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia. 2009;23:519-527.
12. + T-cell responses in patients with chronic lymphocytic leukemia. Leukemia. 2010;24:798-805.
13. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804-811.
14. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204:1849-1861.
15. + T cells. J Immunol. 2006;177:2775-2783.
16. + T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol. 2007;179: 1423-1426.
17. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775-787.
18. Giannopoulos K, Schmitt M, Kowal M et al. Characterization of regulatory T cells in patients with B-cell chronic lympho-cytic leukemia. Oncol Rep. 2008;20:677-682.
19. So T, Lee S W, Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 2008;19:253-262.
20. Kröber A, Bloehdorn J, Hafner S et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol. 2006;24:969-975.
21. Giannopoulos K, Schmitt M, Wlasiuk P et al. High frequency of Th17 T cells in B-cell chronic lymphocytic leukemia. Acta Haemtol Pol. 2008;39:237-244.
22. + T cells without the need to know epitope specificities. Cytometry A. 2008;73:1043-1049.
23. + regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol. 2005;175:32-36.
24. Krammer PH. CD95's deadly mission in the immune system. Nature. 2000;407:789-795.
25. Sauer S, Bruno L, Hertweck A et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA. 2008;105:7797-7802.
26. + regulatory T cells: selfishness under scrutiny. Immunity. 2007;27:417-419.
27. + regulatory T cells. Immunity. 2007;27:493-504.
28. Lio C W, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity. 2008;28:100-111.
29. + T cells in vitro. Transplantation. 2004;78:815-824.